{"id":4549,"date":"2021-08-12T15:48:05","date_gmt":"2021-08-12T20:48:05","guid":{"rendered":"https:\/\/lsom.uthscsa.edu\/stage-pediatrics\/?page_id=4549"},"modified":"2022-04-13T16:36:43","modified_gmt":"2022-04-13T21:36:43","slug":"current-research-trials","status":"publish","type":"page","link":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/","title":{"rendered":"Current Research Trials"},"content":{"rendered":"<div class=\"wpb-content-wrapper\" id=\"wpb-content-root\"><p>[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text]<\/p>\n<h2>Oncology Clinical Trials<\/h2>\n<p><strong>Registry and Biology Protocols<\/strong><\/p>\n<ul>\n<li>Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study:<\/li>\n<li>Neuroblastoma Biology Studies<\/li>\n<li>Renal Tumors Classification, Biology and Banking Study<\/li>\n<\/ul>\n<p><strong>Acute Lymphoblastic Leukemia (ALL) Protocols<\/strong><\/p>\n<ul>\n<li>A Phase 2 Study of the JAK1\/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and\/or JAK Pathway\u2013Mutant Acute Lymphoblastic Leukemia<\/li>\n<li>International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones<\/li>\n<li>A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)<\/li>\n<li>A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly -HR-BALL<\/li>\n<li>A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged &gt;\/=1 to &lt;31 Years Old with First Relapse<\/li>\n<li>Phase 1b\/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia<\/li>\n<\/ul>\n<p><strong>Acute Myeloid Leukemia (AML) Protocols<\/strong><\/p>\n<ul>\n<li>Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome<\/li>\n<li>A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations<\/li>\n<\/ul>\n<p><strong>Central Nervous System (CNS) Protocols<\/strong><\/p>\n<ul>\n<li>A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients<\/li>\n<li>A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin\/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)<\/li>\n<li>A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)<\/li>\n<li>A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular &amp; Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor<\/li>\n<\/ul>\n<p><strong>Hodgkins Disease Protocols<\/strong><\/p>\n<ul>\n<li>A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;\/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma)<\/li>\n<li>A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma<\/li>\n<\/ul>\n<p><strong>Non-Sarcoma Solid Tumor Protocols<\/strong><\/p>\n<ul>\n<li>A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors<\/li>\n<li>A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors &#8211; ANZUP Trial<\/li>\n<li>Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)<\/li>\n<li>Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma<\/li>\n<li>A Phase 2 Randomized Study of Irinotecan\/Temozolomide\/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma<\/li>\n<li>A Randomized Phase 2 Trial of Axitinib\/Nivolumab combination therapy vs single agent Axitinib or Nivolumab for the\u00a0treatment of TFE\/Translocation Renal Cell Carcinoma across all age groups<\/li>\n<\/ul>\n<p><strong>Sarcoma Protocols<\/strong><\/p>\n<ul>\n<li>A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors<\/li>\n<li>Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias<\/li>\n<\/ul>\n<p><strong>Cancer Control and other Non-Therapeutic Protocols<\/strong><\/p>\n<ul>\n<li>Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study<\/li>\n<li>Umbrella Long-Term Follow-Up Protocol<\/li>\n<li>Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer<\/li>\n<li>Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related\u00a0Cardiomyopathy<\/li>\n<li>Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma<\/li>\n<li>StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among AYA Cancer Survivors<\/li>\n<li>Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)<\/li>\n<\/ul>\n<p><strong>Molecular and Pharmacokinetic Protocols<\/strong><\/p>\n<ul>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) &#8211; Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions.<\/li>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations<\/li>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) &#8211; Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes<\/li>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations<\/li>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) &#8211; Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations<\/li>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice Master Version) Screening Protocol<\/li>\n<li>NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice Master Version) Control Document<\/li>\n<li>A Phase I\/II, Multicenter, Open-Label, Multi-Arm Study Evaluating The Safety Toleraility, Pharmacokinetics, And Preliminary Activity of Idasanutlin Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With\u00a0Relapsed\/Refractory Acute Leukemias or Solid Tumors<\/li>\n<li>Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;][vc_single_image image=&#8221;4882&#8243;]\n        <div class=\"panel colorized-border border-colorized-theme single-border single-border-top\"  >\n              <div class=\"text-center\">\n              <div class=\"circle colorized-theme close2x mid-icon\"><span><i class=\"icon-microscope\"><\/i><\/span><\/div>\n                <h2>For More Information<\/h2>\n              <\/div>\n                <div class=\"loose-list line-delimited\"><\/p>\n<ul>\n<li>Phone: \u00a0(210) 562 &#8211; 9149<\/li>\n<li>Email: \u00a0PhoResearchOffice@uthscsa.edu<\/li>\n<\/ul>\n<p><\/div>\n            <\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text] Oncology Clinical Trials Registry and Biology Protocols Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study: Neuroblastoma Biology Studies Renal Tumors Classification, Biology and Banking Study Acute Lymphoblastic Leukemia (ALL) Protocols A Phase 2 Study of the JAK1\/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and\/or JAK Pathway\u2013Mutant Acute [&hellip;]<\/p>\n","protected":false},"author":290,"featured_media":0,"parent":4544,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/child-page.php","meta":{"footnotes":""},"class_list":["post-4549","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Current Research Trials - Pediatrics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current Research Trials - Pediatrics\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text] Oncology Clinical Trials Registry and Biology Protocols Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study: Neuroblastoma Biology Studies Renal Tumors Classification, Biology and Banking Study Acute Lymphoblastic Leukemia (ALL) Protocols A Phase 2 Study of the JAK1\/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and\/or JAK Pathway\u2013Mutant Acute [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Pediatrics\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-13T21:36:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/research\\\/current-research-trials\\\/\",\"url\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/research\\\/current-research-trials\\\/\",\"name\":\"Current Research Trials - Pediatrics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/#website\"},\"datePublished\":\"2021-08-12T20:48:05+00:00\",\"dateModified\":\"2022-04-13T21:36:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/research\\\/current-research-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/research\\\/current-research-trials\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/research\\\/current-research-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Divisions\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Division of Pediatric Hematology-Oncology\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Research\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/divisions\\\/hematology-oncology\\\/research\\\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Current Research Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/#website\",\"url\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/\",\"name\":\"Pediatrics\",\"description\":\"Department of Pediatrics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/pediatrics\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current Research Trials - Pediatrics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/","og_locale":"en_US","og_type":"article","og_title":"Current Research Trials - Pediatrics","og_description":"[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text] Oncology Clinical Trials Registry and Biology Protocols Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study: Neuroblastoma Biology Studies Renal Tumors Classification, Biology and Banking Study Acute Lymphoblastic Leukemia (ALL) Protocols A Phase 2 Study of the JAK1\/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and\/or JAK Pathway\u2013Mutant Acute [&hellip;]","og_url":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/","og_site_name":"Pediatrics","article_modified_time":"2022-04-13T21:36:43+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/","url":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/","name":"Current Research Trials - Pediatrics","isPartOf":{"@id":"https:\/\/lsom.uthscsa.edu\/pediatrics\/#website"},"datePublished":"2021-08-12T20:48:05+00:00","dateModified":"2022-04-13T21:36:43+00:00","breadcrumb":{"@id":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/current-research-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lsom.uthscsa.edu\/pediatrics\/"},{"@type":"ListItem","position":2,"name":"Divisions","item":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/"},{"@type":"ListItem","position":3,"name":"Division of Pediatric Hematology-Oncology","item":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/"},{"@type":"ListItem","position":4,"name":"Research","item":"https:\/\/lsom.uthscsa.edu\/pediatrics\/divisions\/hematology-oncology\/research\/"},{"@type":"ListItem","position":5,"name":"Current Research Trials"}]},{"@type":"WebSite","@id":"https:\/\/lsom.uthscsa.edu\/pediatrics\/#website","url":"https:\/\/lsom.uthscsa.edu\/pediatrics\/","name":"Pediatrics","description":"Department of Pediatrics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lsom.uthscsa.edu\/pediatrics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/pages\/4549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/users\/290"}],"replies":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/comments?post=4549"}],"version-history":[{"count":0,"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/pages\/4549\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/pages\/4544"}],"wp:attachment":[{"href":"https:\/\/lsom.uthscsa.edu\/pediatrics\/wp-json\/wp\/v2\/media?parent=4549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}